Article Text

Download PDFPDF
De novo uterine sarcoma with good response to neo-adjuvant chemotherapy
  1. F. NUMA*,
  3. H. OGATA*,
  4. S. NAWATA*,
  6. T. EMOTO*,
  7. K. KAWASAKI*,
  8. H. HIRAKAWA*,
  9. M. SASE*,
  10. A. OGA and
  11. H. KATO*
  1. * Department of Reproductive, Pediatric and Infectious Science, Yamaguchi University School of Medicine, Yamaguchi, Japan
  2. †Department of Molecular Pathology, Molecular Science and Applied Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
  1. Address correspondence and reprint requests to: Fumitaka Numa, Department of Reproductive, Pediatric and Infectious Science, Yamaguchi University School of Medicine, 1-1-1 Minami Kogushi, Ube, Yamaguchi 755–8505, Japan, Email: fnuma{at}


We report here the extremely rare case of a 28-year-old woman with advanced stage uterine sarcoma arising soon after a cesarean section. She underwent an abdominal cesarean section because of a breech presentation. At the time of the procedure, there were no abnormal findings such as leiomyoma of the uterus in the abdominal cavity. One year later, she was referred to our hospital because of a large abdominal tumor. Transabdominal power Doppler ultrasonography and magnetic resonance imaging (MRI) showed a large hypervascular tumor in the abdominal cavity. Her serum levels, for the two tumor markers carbohydrate antigen CA125 and LDH, were elevated, at 219 U/ml (< 35 U/ml) and 862 IU/l (115 U/ml−217 U/ml), respectively. On the basis of a diagnosis of malignant tumor of gynecological origin, exploratory laparotomy was performed, and through biopsy, the tumor was found to be advanced undifferentiated uterine sarcoma. She exhibited a good response to neoadjuvant chemotherapy consisting of cisplatin, epirubicin, and dimethyltriazenoimidazole carboxamide (DTIC) every 28 days, which was successfully followed by a hysterectomy.

  • cesarean section
  • cisplatin
  • dimethyltriazenoimidazole carboxamide (DTIC)
  • epirubicin
  • uterine sarcoma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.